VA
PRCT icon

Vident Advisory’s Procept Biorobotics PRCT Stock Holding History

Vident Advisory’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,133
Closed -$204K – 1491
2024
Q1 		$204K Buy
+4,133
New +$197K ﹤0.01% 1207

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vident Advisory's PRCT Position: Q2 2024 in Review

Vident Advisory sold out of Procept Biorobotics (PRCT) in Q2 2024, closing a stake of 4,133 shares — an estimated $204K sold.

Vident Advisory first reported a position in PRCT in Q1 2024 and held it in 1 quarter. The position peaked at $204K in Q1 2024. 201 funds tracked by Wall St. Rank hold PRCT as of Q2 2024.

  • Vident Advisory reported no remaining Procept Biorobotics position as of Q2 2024 after selling out during the quarter.
  • Vident Advisory sold 4,133 Procept Biorobotics shares in Q2 2024, an estimated $204K.
  • Vident Advisory first reported a position in Procept Biorobotics in Q1 2024 and held it in 1 quarter.
  • Vident Advisory's Procept Biorobotics position peaked at $204K in Q1 2024.
  • 201 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2024.

Based on Vident Advisory's 13F filing for Q2 2024, filed 14 Aug 2024.